Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Financing Activities (2021 - 2025)

Prime Medicine's Cash from Financing Activities history spans 5 years, with the latest figure at $562000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 56100.0% year-over-year to $562000.0; the TTM value through Dec 2025 reached $151.5 million, down 22.65%, while the annual FY2025 figure was $151.5 million, 22.65% down from the prior year.
  • Cash from Financing Activities reached $562000.0 in Q4 2025 per PRME's latest filing, down from $144.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $184.1 million in Q4 2022 to a low of -$1.3 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $31.1 million, with a median of $194000.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: crashed 99.89% in 2023, then skyrocketed 231263.24% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$1.1 million in 2021, then surged by 17049.63% to $184.1 million in 2022, then plummeted by 99.89% to $194000.0 in 2023, then crashed by 99.48% to $1000.0 in 2024, then surged by 56100.0% to $562000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRME's Cash from Financing Activities are $562000.0 (Q4 2025), $144.8 million (Q3 2025), and $197000.0 (Q2 2025).